Cover Image

Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study

Recombinant human pentraxin-2 (rhPTX-2) significantly decreased decline in percent predicted forced vital capacity (FVC) and stabilized 6-min walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF) during the 28-week, placebo-controlled, randomized period of the Phase II PRM-151-20...

Full description

Saved in:
Bibliographic Details
Main Authors: Raghu, Ganesh (Author) , Hamblin, Mark J. (Author) , Brown, A. Whitney (Author) , Golden, Jeffrey A. (Author) , Ho, Lawrence A. (Author) , Wijsenbeek, Marlies S. (Author) , Vasakova, Martina (Author) , Pesci, Alberto (Author) , Antin-Ozerkis, Danielle E. (Author) , Meyer, Keith C. (Author) , Kreuter, Michael (Author) , Burgess, Tracy (Author) , Kamath, Nikhil (Author) , Donaldson, Francis (Author) , Richeldi, Luca (Author)
Format: Article (Journal)
Language:English
Published: 21 May 2022
In: Respiratory research
Year: 2022, Volume: 23, Pages: 1-12
ISSN:1465-993X
DOI:10.1186/s12931-022-02047-0
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12931-022-02047-0
Get full text
Author Notes:Ganesh Raghu, Mark J. Hamblin, A. Whitney Brown, Jeffrey A. Golden, Lawrence A. Ho, Marlies S. Wijsenbeek, Martina Vasakova, Alberto Pesci, Danielle E. Antin-Ozerkis, Keith C. Meyer, Michael Kreuter, Tracy Burgess, Nikhil Kamath, Francis Donaldson and Luca Richeldi
Description
Summary:Recombinant human pentraxin-2 (rhPTX-2) significantly decreased decline in percent predicted forced vital capacity (FVC) and stabilized 6-min walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF) during the 28-week, placebo-controlled, randomized period of the Phase II PRM-151-202 study. Interim (76-week) data from the open-label extension (OLE) demonstrated sustained safety and efficacy with rhPTX-2 treatment. Here, we present the entire long-term OLE safety and efficacy data to 128 weeks.
Item Description:Gesehen am 01.07.2022
Physical Description:Online Resource
ISSN:1465-993X
DOI:10.1186/s12931-022-02047-0

Similar Items